Trial Profile
A Randomized Phase II Study of Two Different Schedules of RAD001C in Patients With Recurrent/Metastatic Breast Cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Aug 2023
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Therapeutic Use
- 18 Jan 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
- 18 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Aug 2009 Results have been reported in the Journal of Clinical Oncology.